The J.P. Morgan Healthcare Conference brings thousands of industry professionals together in San Francisco each year for a week of conversation on innovation, therapeutic advancement and the future of healthcare. As is typical for the event, JPM 2026 was a whirlwind – both intense and energizing, painting a picture of a bold and expanding industry. It was exciting for Ionis to contribute to the discussion as we highlighted our commitment to driving better futures for people living with serious diseases.
2025 was a defining year for Ionis, hallmarked by our first two independent launches as a commercial stage biotech company: the first approved medicine for familial chylomicronemia syndrome and the first RNA-targeted medicine for hereditary angioedema. The encouraging success we’ve seen to date with these medicines reflects strong and focused execution across discovery, development and commercialization as we deliver our medicines to the people who need them.
And we’re not slowing down in 2026, poised for another transformative year. In our presentation, I shared highlights from the past year and outlined key anticipated milestones.
So, what’s next? Take a look at our upcoming year by the numbers:
- 5 Phase 3 Data Readouts from our partnered programs, demonstrating the strength and broad applicability of our technology platform. We have one of the deepest and most exciting late-stage pipelines in the industry, with 11 medicines in Phase 3 development today.
- 4 Planned NDA Submissions spanning our Ionis-owned and partnered programs, reflecting both the breadth and momentum of our portfolio. Building on our established success to date, our teams stand ready to execute.
- 3 Anticipated Launches of Ionis-discovered medicines across rare and highly prevalent diseases for which there are no or limited treatment options available today, including:
- A transformational medicine for patients living with debilitating symptoms resulting from high triglycerides,
- The first and only investigational medicine to demonstrate clinically meaningful and disease-modifying impact in Alexander disease, and
- The first and only investigational medicine to demonstrate clinically meaningful functional cure rate for chronic hepatitis B, in partnership with GSK
- 2 Industry-Leading Focus Areas, advancing our mid- and late-stage portfolios in cardiometabolic and neurological diseases. We are building on our proven platform and capabilities for delivering groundbreaking medicine and leading the way in these areas.
- 1 Goal: To transform the lives of people living with serious diseases.
Our future at Ionis is brighter than ever, with a leading portfolio that has and will continue to deliver groundbreaking medicines. 2026 is a catalyst-rich year in which we expect to drive accelerating growth and sustained value creation for our shareholders, our employees and – most importantly – for the patient communities we serve.
Through compassion, discipline and relentless pursuit of scientific excellence, I am confident we will be successful and look forward to an exciting year ahead.
If you’re interested in learning more, take a look at our full presentation here.